NCT02427165View on ClinicalTrials.gov

Comparison of RPL554 With Placebo and Salbutamol in Asthmatic Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

29

Participants

Timeline

Start Date

April 30, 2015

Primary Completion Date

November 30, 2015

Study Completion Date

November 30, 2015

Conditions
Asthma
Interventions
DRUG

RPL554

A dual PDE3 and PDE4 inhibitor

DRUG

Salbutamol

a beta-2 receptor agonist

DRUG

Placebo

RPL554 placebo containing no active ingredients

Trial Locations (2)

Unknown

Skane University Hospital, Lund

Celerion, Belfast

All Listed Sponsors
lead

Verona Pharma plc

INDUSTRY

NCT02427165 - Comparison of RPL554 With Placebo and Salbutamol in Asthmatic Patients | Biotech Hunter | Biotech Hunter